Flora Growth Acquires CBD Brand Masaya

$FLGC
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $FLGC alert in real time by email

Flora Growth Corp. (NASDAQ:FLGC) ("Flora" or the "Company"), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, announced today that it has entered into an agreement with leading cell biologist, Dr. Annabelle Manalo-Morgan, Ph.D., to acquire her brand Masaya, together with its patent-pending CBD formulations. Created by Dr. Annabelle and backed by her research, Masaya's formulations of pure, potent CBD oil are 100% THC-free and have a long track record of positive testimonials collected over years of use. Flora intends to distribute the brand and its formulations worldwide.

Masaya will become an owned Flora brand sold in the US and will be the first offering from Flora Life Sciences. In addition, it is expected that the original patent-pending formulation, Masaya Pure, will be used in Flora's current clinical trials with the University of Manchester in the UK. The formulation is also in the process of being registered with the Colombian regulatory agency, INVIMA, as one of the first distribution steps beyond the US.

"We are excited to announce the acquisition of Masaya. The brand's formulation was developed by Dr. Annabelle for her son and has since been used by thousands of consumers. Amplifying Dr. Annabelle and her son's beautiful story and improving the well-being of people around the world is our aim," Flora's Chairman and CEO Luis Merchan said. "This acquisition allows us to deliver on our promise to invest in safe, thorough, cutting-edge scientific research that can bring meaningful change via an efficacious and accessible product offering for people worldwide."

As a member of Flora's Board of Directors and as the Company's Scientific Advisor, Dr. Annabelle is responsible for leading Flora's global research initiatives, including Flora's ongoing clinical trial on the use of cannabinoids with patients who have fibromyalgia in partnership with the University of Manchester in the UK. Those clinical trials are expected to expand into research on the use of cannabinoids for other medical indications in the UK, at Flora's research facilities in Colombia, and in the US. It is anticipated that proceeds from the sale of Masaya products will contribute to the funding of this vital research.

After the birth of her son Macario in 2016, Dr. Annabelle endured watching him suffer from as many as 200 seizures per day which led doctors to remove 38 percent of his brain. Relentlessly, Dr. Annabelle searched for alternative solutions for Macario and eventually discovered CBD, which has helped Macario, now six, become a happy and thriving child.

"After my experience with my son Macario, I am very excited to bring Masaya to more consumers worldwide, to do my very best to help as many people as I can," said Dr. Annabelle, Lead Scientific Advisor and Director of Flora. "Both consumers and the global scientific community deserve more research and data on the science behind CBD, and I feel truly grateful to be working with the Flora team to help develop some of the highest-quality, scientifically vetted products in the world."

Dr. Annabelle is a scientist, educator, author, mother of five, and a respected key opinion leader. She is a cell and developmental biologist with a doctorate from Vanderbilt University in Nashville, Tennessee, with a background in neuroscience from Georgetown University. She earned her Ph.D. in Cell and Developmental Biology with a focus in Cardio-Oncology and has since become a philanthropist and entrepreneur focused on pharmaceutical innovation and clinical trial research in medical cannabis.

About Flora Growth Corp.

Flora is building a connected, design-led collective of plant-based wellness and lifestyle brands delivering the most compelling customer experiences in the world, one community at a time. As the operator of one of the most extensive outdoor cannabis cultivation facilities, Flora leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its commercial, house of brands, and life sciences divisions. Visit www.floragrowth.com or follow @floragrowthcorp on social media for more information.

Cautionary Statement Concerning Forward-Looking Statements

This document contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; our environmental and sustainability practices and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this document and other statements made from time to time by us or our representatives may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, or the forward-looking events discussed in this document and other statements made from time to time by us or our representatives not occurring, except as may be required by applicable law.

Get the next $FLGC alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$FLGC

DatePrice TargetRatingAnalyst
11/25/2024$4.00Buy
Aegis Capital
10/13/2021$10.00Buy
Roth Capital
6/23/2021$6.00Buy
MKM Partners
More analyst ratings

$FLGC
Press Releases

Fastest customizable press release news feed in the world

See more
  • Flora Growth Corp. Closes Acquisition of Australian Vaporizers

    Fort Lauderdale, Florida--(Newsfile Corp. - June 5, 2024) - Flora Growth Corp. (NASDAQ:FLGC) ("Flora" or the "Company") has entered into a share purchase agreement (the "Agreement") to acquire of all of the issued and outstanding shares of Australian Vaporizers Pty Limited ("Australian Vaporizers") in exchange for 550,000 Flora common shares, valued at $0.7 million based on the closing price of Flora's common shares on June 3, 2024, subject to working capital adjustments. The transaction closed on June 4, 2024. Australian Vaporizers was founded in 2010 and has become one of the largest online retailers of vaporizers, hardware, and accessories in Australia. It is an online expert for aromathe

    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Lifeist Sells Australian Vapes

    TORONTO, June 05, 2024 (GLOBE NEWSWIRE) -- Lifeist Wellness Inc. ("Lifeist" or the "Company") (TSXV:LFST) (FRANKFURT: M5B) (OTC:LFSWF), a health-tech company that leverages advancements in science and technology to build breakthrough companies that transform human wellness, today announced the sale of Australian Vaporizers Pty Ltd. ("Aussie Vapes"), its wholly owned Australian subsidiary to Flora Growth Corp. (NASDAQ:FLGC) ("Flora"), a U.S.-based consumer-packaged goods and pharmaceutical distributor serving all 50 states and 28 countries. The sale was completed through a share purchase agreement (the "SPA") entered into between Lifeist, as vendor, and Flora Growth Corp, as purchaser, purs

    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • TSX Venture Exchange Stock Maintenance Bulletins

    VANCOUVER, BC, June 4, 2024 /CNW/ - TSX VENTURE COMPANIES BULLETIN V2024-1678 CEAPRO INC. ("CZO")BULLETIN TYPE: Plan of Arrangement, Remain Halted, DelistBULLETIN DATE: June 4, 2024TSX Venture Tier 2 Company  TSX Venture Exchange (the "Exchange") has accepted for filing documentation in connection with an arrangement agreement dated December 14, 2023, as amended on January 16, 2024, between Ceapro Inc. ("Ceapro") and Aeterna Zentaris Inc. ("Aeterna"), pursuant to which Aeterna acquired all of the issued and outstanding common shares of Ceapro by way of a plan of arrangement under the Canada Business Corporations Act (the "Arrangement"). Under the terms of the Arrangement, Ceapro shareholder

    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

$FLGC
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$FLGC
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$FLGC
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$FLGC
SEC Filings

See more

$FLGC
Leadership Updates

Live Leadership Updates

See more
  • Flora Growth Corp. Appoints Clifford Starke as Chief Executive Officer and Dany Vaiman as Chief Financial Officer; Regains Compliance with NASDAQ Minimum Bid Requirement

    Fort Lauderdale, Florida--(Newsfile Corp. - June 27, 2023) - Flora Growth Corp. (NASDAQ:FLGC) ("Flora" or the "Company"), a consumer-packaged goods leader serving all 50 states with 15,000+ points of distribution around the world and a pharmaceutical distributor in 28 countries, announced today that Clifford Starke has been appointed as Chief Executive Officer to lead its global operations and Dany Vaiman has been appointed as Chief Financial Officer. Mr. Starke, who previously served as President of the Company, takes over for Hussein Rakine, who resigned as CEO but will remain on the Company's Board of Directors. Mr. Rakine expressed his confidence in the appointment, stating, "Clifford's

    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Flora Growth Corp. Announces the Appointment of Hussein Rakine as CEO and Member of the Board of Directors

    Flora Growth Corp. (NASDAQ:FLGC) ("Flora" or the "Company") a leading cultivator, manufacturer and distributor of global cannabis products and brands, today announced that its board of directors (the "Board") accepted the resignation of Luis Merchan as Chairman of the Board and the Company's Chief Executive Officer (CEO). To fill the vacancies created by Mr. Merchan's resignation, the Board has appointed JustCBD founder, Hussein Rakine, as CEO and member of the board of directors. Of the appointment, former-Chairman and CEO, Luis Merchan said, "At Flora we have consistently placed human capital as a critical part of our M&A strategy. That's why today we are honored to have the former foun

    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • CBD Oil Market to Hit Nearly US$137 Billion by 2029

    FN Media Group Presents Microsmallcap.com Market Commentary NEW YORK, Aug. 23, 2022 /PRNewswire/ -- The CBD oil market is expected to witness an astounding CAGR of 38.90% from 2021 until 2029, climbing from $9.86 billion to $136.64 billion. There are several reasons behind the projected growth such a growing number of CBD-infused skincare products, increased use of THC and CBD in pain management and treatment, rising sales in both retail stores and online, expanding research, and increasing demand for ingestible products. Governments around the world have also begun opening up more doors for CBD, with a recent Health Canada report suggesting legal framework to broaden retail CBD sales across

    $CGC
    $CRON
    $FLGC
    $OGI
    Medicinal Chemicals and Botanical Products
    Health Care
    Biotechnology: Pharmaceutical Preparations

$FLGC
Financials

Live finance-specific insights

See more
  • Flora Growth Sets Third Quarter 2022 Conference Call for November 28, 2022, at 4:30 P.M. ET

    Flora Growth Corp. (NASDAQ:FLGC) ("Flora'' or the "Company"), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, will host its third quarter 2022 earnings call via webcast on Monday, November 28 at 4:30 p.m. ET. During the webcast, Flora management will deliver financial and operational results for the third quarter ended September 30, 2022, and provide updates on Flora's commercial wholesale operations, house of brands and life sciences division strategies. Following the webcast, Flora management will open the call to analysts, media and investors in a Q&A format. Live Webcast Details Date: Monday, November 28, 2022 Time: 4:30 p.m. ET

    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Flora Growth to Host Webcast Discussing M&A Activity and International Market Opportunities - Wednesday, October 26, 2022

    Flora Growth Corp. (NASDAQ:FLGC) ("Flora'' or the "Company"), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, announced today that the Company will be hosting an analyst call on Wednesday, October 26, 2022, at 02:00 p.m. EST via webcast to discuss Flora Growth's recent M&A activity and strategic growth opportunities. The conference call and live webcast will invite analysts to pose questions to Flora and Franchise Global Health's leadership teams regarding the recent announcement of the definitive agreement of acquisition between the two companies and the opportunities within the cannabis industry on the global stage. To access this ca

    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Flora Growth Awarded Best M&A Deal at Benzinga Cannabis Capital Conference

    Flora Growth Corp. (NASDAQ:FLGC) ("Flora" or the "Company"), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, today announced that the Company received the Best M&A Deal award at Benzinga's 2022 Cannabis Capital Conference in Chicago. "We are honored to receive the award for Best M&A Deal at the Benzinga Cannabis Capital Conference, which recognizes our strategic M&A objectives including acquiring products, expertise, expanding distribution, and customers," said Luis Merchan, Chairman and CEO of Flora. Flora completed the acquisition of JustCBD in February 2022, and it immediately offered the Company an established CPG brand with a por

    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

$FLGC
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more